Company profile
Black Diamond Therapeutics, Inc.
NASDAQ: BDTX · Healthcare · Biotechnology
#391 of 1,418 Healthcare companies by revenue
EA Score
60CFH 73DQ 44GM —SS 45
v0.1 · 55/100 weight · provisional
↑ net margin, return on assets · ↓ Piotroski F, disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
$22.4M
Employees
21
as of 2026-08-18
Market cap
$116.6M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$70.0M$70.0M2025
Net income$22.4M$22.4M2025
Operating income$12.5M$12.5M2025
Total assets$143.0M$143.0M2025
Liabilities$30.8M$30.8M2025
Equity$112.2M$112.2M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY20
FY20
FY20
FY25
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is Black Diamond Therapeutics, Inc.’s revenue?
Black Diamond Therapeutics, Inc. booked $70.0M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a 32.0% net margin.
Peers · Healthcare
Avita Medical Inc.50DViridian Therapeutics, Inc.66BCodexis, Inc.61CPersonalis, Inc.59CRockwell Medical, Inc.60CVir Biotechnology, Inc.48DNeighbors
Middlesex →Key facts
CEOMark A. Velleca
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: BDTX
Employees21
IPO date2020-01-31
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.